Table 2.
Clinicopathologic/treatment characteristics (N = 43)
| Variable | Overall |
|---|---|
| Initial NA treatment regimen, n (%) | 43 (100) |
| FOLFIRINOX | 38 (88.4) |
| Gemcitabine/nab-paclitaxel | 7 (16.3) |
| FOLFIRI | 1 (0.9) |
| Chemoradiation | 1 (0.9) |
| NA chemoradiation, n (%) | 23 (53.5) |
| Capecitabine | 8 (34.7) |
| 5-Fluorouracil | 15 (65.2) |
| Surgery attempted, n (%) | 28 (65.1) |
| Surgery completed, n (%) | 19 (44.1) |
| Pancreaticoduodenectomy | 17 (89.4) |
| Distal pancreatectomy | 2 (10.6) |
| Tumor size (cm), median (range) | 2.5 (0–5.2) |
| Treatment response, n (%) | |
| Complete | 2 (10.5) |
| Extensive | 2 (10.5) |
| Moderate | 11 (57.8) |
| Absent | 3 (16.7) |
| Nodal disease (present), n (%) | 8 (42.1) |
| Margin status (negative), n (%) | 14 (73.6) |
| Lymphovascular invasion (present), n (%) | 4 (21.1) |
| Perineural invasion (present), n (%) | 8 (42.1) |
| Irreversible electroporation, n (%) | 7 (16.3) |
| Adjuvant/postresection | 4 (57.1) |
| Primary/unresectable | 3 (42.9) |
| Adjuvant chemotherapy, n (%) | 15 (78.9) |
| Adjuvant chemoradiation, n (%) | 5 (26.3) |